| Literature DB >> 26759823 |
Deep Pooja1, Lakshmi Tunki1, Hitesh Kulhari2, Bharathi B Reddy1, Ramakrishna Sistla1.
Abstract
This data article contains the data related to the research article "Characterization, biorecognitive activity and stability of WGA grafted lipid nanostructures for the controlled delivery of rifampicin" (Pooja et al. 2015) [1]. In the present study, SLN were prepared by a single emulsification-solvent evaporation method and the various steps of SLN preparation are shown in a flow chart. The preparation of SLN was optimized for various formulation variables including type and quantity of lipid, surfactant, amount of co-surfactant and volume of organic phase. Similarly, effect of variables related to homogezation, sonication and stirring processes, on the size and surface potential of SLN was determined and optimized.Entities:
Keywords: Formulation parameters; Optimization; Process variables; Single emulsification-solvent evaporation; Solid lipid nanoparticles
Year: 2015 PMID: 26759823 PMCID: PMC4683325 DOI: 10.1016/j.dib.2015.11.038
Source DB: PubMed Journal: Data Brief ISSN: 2352-3409
Fig. 1Flow chart representing the preparation of solid lipid nanoparticles.
Optimization of various formulation parameters for the preparation of solid lipid nanoparticles.
| Formulation | Variable | PD (nm) | PDI | ZP (mV) | |
|---|---|---|---|---|---|
| F1 | GMS | 100 | 55.53±2.4 | 0.23±0.04 | −23.2±2.1 |
| F2 | Tristearin | 100 | 157.5±6.7 | 0.35±0.11 | −26.9±2.3 |
| F3 | Tripalmitin | 100 | 119.5±3.9 | 0.43±0.08 | −22.1±1.9 |
| F4 | GMS | 80 | 49.28±3.1 | 0.27±0.09 | −21.8±1.6 |
| F1 | GMS | 100 | 55.53±2.4 | 0.23±0.04 | −23.2±2.1 |
| F6 | GMS | 120 | 55.09±3.7 | 0.30±0.02 | −29.7±2.3 |
| F7 | Tween 80 | 1 | 66.67±2.5 | 0.36±0.12 | −31.8±2.4 |
| F1 | Tween 80 | 1.5 | 55.53±2.4 | 0.23±0.04 | −23.2±2.1 |
| F8 | Tween 80 | 2 | 133.2±5.6 | 0.27±0.08 | −26.6±1.8 |
| F9 | Poloxomer 188 | 1 | 61.4±4.4 | 0.38±0.09 | −29.9±2.3 |
| F10 | Poloxomer 188 | 1.5 | 65.7±3.9 | 0.40±0.12 | −26.4±2.1 |
| F11 | Poloxomer 188 | 2 | 64.9±2.8 | 0.39±0.10 | −23.5±2.5 |
| F12 | PVA | 1 | 120.92±6.1 | 0.15±0.09 | −32.0±1.9 |
| F13 | PVA | 1.5 | 108.84±4.3 | 0.20±0.07 | −26.6±2.4 |
| F14 | PVA | 2 | 102.86±4.8 | 0.21±0.11 | −24.5±1.8 |
| F15 | CHCl3 | 1 | 48.91±2.4 | 0.36±0.11 | −19.6±1.4 |
| F16 | CHCl3 | 2 | 52.81±1.9 | 0.21±0.07 | −24.3±2.6 |
| F1 | CHCl3 | 3 | 55.53±2.4 | 0.23±0.04 | −23.2±2.1 |
| F17 | CHCl3 | 5 | 47.73±2.6 | 0.25±0.04 | −23.7±2.3 |
| F16 | lecithin soy | 20 | 52.81±1.9 | 0.21±0.07 | −24.3±2.6 |
| F18 | lecithin soy | 30 | 47.54±2.3 | 0.21±0.09 | −25.5±1.8 |
| F19 | lecithin soy | 40 | 50.32±3.1 | 0.28±0.10 | −28.6±2.4 |
GMS: Glyceryl monostearte; PVA: Polyvinyl alcohol; PD: Particle diameter, PDI: Polydispersity index; ZP: Zeta potential.
Optimization of various process variables for preparation solid lipid nanoparticles.
| Formulation | Variable | PD (nm) | PDI | ZP (mV) |
|---|---|---|---|---|
| F20 | 5000 | 64.67±4.8 | 0.56±0.03 | −27.5±2.5 |
| F18 | 8000 | 47.54±2.3 | 0.21±0.09 | −25.5±1.8 |
| 21 | 11000 | 44.43±3.1 | 0.26±0.03 | −26.5±2.1 |
| F22 | 3 | 157.92±5.7 | 0.45±0.05 | −30.3±3.1 |
| F23 | 4 | 76.21±3.9 | 0.28±0.07 | −25.8±2.8 |
| F21 | 5 | 44.43±3.1 | 0.26±0.03 | −26.5±2.1 |
| F24 | 6 | 71.23±4.8 | 0.29±0.11 | −23.9±2.7 |
| F25 | 5 | >500 | – | – |
| F26 | 10 | 135.45±6.7 | 0.32±0.13 | −27.1±2.9 |
| F21 | 15 | 44.43±3.1 | 0.26±0.03 | −26.5±2.1 |
| F27 | 20 | 49.89±2.8 | 0.24±0.09 | −25.8±2.6 |
| F28 | 800 | 59.02±3.9 | 0.25±0.05 | −20.1±1.9 |
| F21 | 1000 | 44.43±3.1 | 0.26±0.03 | −26.5±2.1 |
| F29 | 1200 | 67.82±4.2 | 0.27±0.02 | −22.9±2.5 |
| F30 | 1 | 69.48±4.5 | 0.42±0.07 | −28.4±2.7 |
| F31 | 2 | 57.37±5.1 | 0.31±0.05 | −26.4±1.8 |
| F21 | 3 | 44.43±3.1 | 0.26±0.03 | −26.5±2.1 |
| F32 | 4 | 61.34±3.8 | 0.25±0.09 | −26.2±2.5 |
| Subject area | Chemistry, lipids and biology |
| More specific subject area | Targeted nanomedicine |
| Type of data | Table and figure |
| How data was acquired | Particle size, polydispersity index and surface charge (Zetasizer, NanoZS, Malvern) |
| Data format | Raw and analyzed |
| Experimental factors | Formulation and process parameters were changed for optimization of size and zeta potential of nanoparticles. |
| Experimental features | Various formulations were prepared by single emulsification- solvent evaporation method to get nanoparticles of desired size and zeta potential. |
| Data source location | NA |
| Data accessibility | The data are presented in this article |